Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IMTX
stocks logo

IMTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
11.39M
-81.23%
-0.476
-205.04%
14.04M
-32.05%
-0.452
+23.18%
14.27M
+158.1%
-0.475
-29.85%
Estimates Revision
The market is revising Downward the revenue expectations for Immatics N.V. (IMTX) for FY2025, with the revenue forecasts being adjusted by -0.36% over the past three months. During the same period, the stock price has changed by 89.62%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.36%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.19%
In Past 3 Month
Stock Price
Go Up
up Image
+89.62%
In Past 3 Month
Wall Street analysts forecast IMTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMTX is 16.25 USD with a low forecast of 11.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast IMTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMTX is 16.25 USD with a low forecast of 11.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.870
sliders
Low
11.00
Averages
16.25
High
23.00
Current: 11.870
sliders
Low
11.00
Averages
16.25
High
23.00
Guggenheim
NULL -> Buy
maintain
$16 -> $19
2025-11-18
Reason
Guggenheim
Price Target
$16 -> $19
2025-11-18
maintain
NULL -> Buy
Reason
Guggenheim raised the firm's price target on Immatics to $19 from $16 and keeps a Buy rating on the shares. The firm is updating its model for Q3 results and quarterly trends as well as last week's clinical update to include probability-adjusted estimates for IMA402 in melanoma and ovarian cancer, the analyst tells investors.
Mizuho
Graig Suvannavejh
maintain
$16 -> $19
2025-10-29
Reason
Mizuho
Graig Suvannavejh
Price Target
$16 -> $19
2025-10-29
maintain
Reason
Mizuho analyst Graig Suvannavejh raised the firm's price target on Immatics to $19 from $16 and keeps an Outperform rating on the shares.
Guggenheim
Paul Jeng
Buy
initiated
$16
2025-09-17
Reason
Guggenheim
Paul Jeng
Price Target
$16
2025-09-17
initiated
Buy
Reason
Guggenheim analyst Paul Jeng initiated coverage of Immatics with a Buy rating and $16 price target.
Guggenheim
Paul Jeng
initiated
$16
2025-09-17
Reason
Guggenheim
Paul Jeng
Price Target
$16
2025-09-17
initiated
Reason
Guggenheim analyst Paul Jeng initiated coverage of Immatics with a Buy rating and $16 price target. Immatics is a leading biotech in the T cell receptor immunotherapies space with a broad pipeline of clinical-stage assets, the analyst tells investors in a research note. The firm sees an attractive risk/reward at current share levels given the company's late-stage lead asset anzutresgene autoleucel, which is targeting a "high unmet need" market in metastatic melanoma.
Deutsche Bank
Buy
initiated
$10
2025-05-28
Reason
Deutsche Bank
Price Target
$10
2025-05-28
initiated
Buy
Reason
Cantor Fitzgerald
Eric Schmidt
Buy
Reiterates
n/a
2025-04-01
Reason
Cantor Fitzgerald
Eric Schmidt
Price Target
n/a
2025-04-01
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Immatics NV (IMTX.O) is -6.33, compared to its 5-year average forward P/E of -1.33. For a more detailed relative valuation and DCF analysis to assess Immatics NV 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.33
Current PE
-6.33
Overvalued PE
0.99
Undervalued PE
-3.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.33
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.35
Undervalued EV/EBITDA
-8.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
11.63
Current PS
0.00
Overvalued PS
16.51
Undervalued PS
6.74
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

IMTX News & Events

Events Timeline

(ET)
2025-12-05
06:10:00
New
Immatics Agrees to Sell 12.5M Ordinary Shares at $10.00 Each
select
2025-11-17 (ET)
2025-11-17
07:05:16
Immatics Announces Q3 EPS of EUR 0.42, Up from EUR 0.08 Year-Over-Year
select
2025-11-12 (ET)
2025-11-12
07:29:08
Immatics reveals new Phase 1a dose escalation results for IMA402 and IMA401.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
19:21 PMGlobenewswire
Immatics Sells 12.5M Shares at $10 Each, Raising $125M
  • Funding Scale: Immatics has announced the sale of 12,500,000 ordinary shares at $10 each, expected to raise $125 million, which will provide crucial funding for the company's clinical development initiatives.
  • Underwriter Lineup: The offering is being managed by Jefferies, Leerink Partners, and Cantor, reflecting market confidence in Immatics' future growth and potentially enhancing its reputation in the biopharmaceutical sector.
  • Transaction Timeline: The offering is expected to close on December 8, 2025, subject to customary closing conditions, allowing the company to quickly access funds to support its research projects.
  • Market Reaction Expectations: This financing will bolster Immatics' research capabilities in precision targeting of PRAME, potentially enhancing its competitive position in cancer treatment, particularly in therapies targeting over 50 types of cancer.
[object Object]
Preview
9.5
11-13NASDAQ.COM
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections

  • Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.

  • Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.

  • Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.

  • Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.

[object Object]
Preview
9.0
10-20Newsfilter
Immatics Showcases Promising Anti-Tumor Effects of Anzu-cel PRAME Cell Therapy for Metastatic Uveal Melanoma at ESMO 2025 Presidential Symposium

  • Clinical Trial Results: An ongoing Phase 1b trial of anzu-cel (PRAME cell therapy) in 16 patients with metastatic uveal melanoma shows a confirmed objective response rate of 67%, with a median duration of response of 11 months and median progression-free survival of 8.5 months.

  • Safety and Tolerability: Anzu-cel demonstrates a favorable tolerability profile, with manageable treatment-emergent adverse events primarily related to cytopenias and cytokine release syndrome, indicating its potential as a treatment option for this difficult-to-treat cancer.

  • Future Development: Due to the promising results, Immatics has initiated a Phase 2 cohort study for anzu-cel in metastatic uveal melanoma, aiming to expand its application in this area of high unmet medical need.

  • Company Overview: Immatics is a clinical-stage biopharmaceutical company focused on precision targeting of PRAME, with a robust pipeline of therapies aimed at various cancers, including ongoing trials for both uveal and cutaneous melanoma.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Immatics NV (IMTX) stock price today?

The current price of IMTX is 11.87 USD — it has increased 14.8 % in the last trading day.

arrow icon

What is Immatics NV (IMTX)'s business?

Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

arrow icon

What is the price predicton of IMTX Stock?

Wall Street analysts forecast IMTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMTX is 16.25 USD with a low forecast of 11.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Immatics NV (IMTX)'s revenue for the last quarter?

Immatics NV revenue for the last quarter amounts to 5.19M USD, decreased -89.74 % YoY.

arrow icon

What is Immatics NV (IMTX)'s earnings per share (EPS) for the last quarter?

Immatics NV. EPS for the last quarter amounts to -0.42 USD, increased 425.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Immatics NV (IMTX)'s fundamentals?

The market is revising Downward the revenue expectations for Immatics N.V. (IMTX) for FY2025, with the revenue forecasts being adjusted by -0.36% over the past three months. During the same period, the stock price has changed by 89.62%.
arrow icon

How many employees does Immatics NV (IMTX). have?

Immatics NV (IMTX) has 297 emplpoyees as of December 05 2025.

arrow icon

What is Immatics NV (IMTX) market cap?

Today IMTX has the market capitalization of 1.45B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free